Trevi Therapeutics, Inc. (TRVI) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Trevi Therapeutics, Inc. (TRVI).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $7.00

Daily Change: -$0.27 / 3.86%

Daily Range: $7.00 - $7.31

Market Cap: $888,811,520

Daily Volume: 1,124,861

Performance Metrics

1 Week: -1.42%

1 Month: 18.31%

3 Months: 9.61%

6 Months: 73.40%

1 Year: 179.7%

YTD: 77.18%

Company Details

Employees: 26

Sector: Health technology

Industry: Biotechnology

Country:

Details

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Selected stocks

Pinnacle West Capital Corporation (PNW)

Portland General Electric Co (POR)

PPL Corporation (PPL)